<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213807</url>
  </required_header>
  <id_info>
    <org_study_id>ANT-004</org_study_id>
    <nct_id>NCT04213807</nct_id>
  </id_info>
  <brief_title>A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation</brief_title>
  <official_title>A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Anthos Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, subject and Investigator-blinded,
      placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the
      safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in
      patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or
      peripheral embolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of FXI at trough after third dose (Day 91) at different dose levels of MAA868</measure>
    <time_frame>Day 91</time_frame>
    <description>Occurrence of achieving ≥50%, ≥80%, or ≥90% inhibition of FXI (&lt;50%, &lt;20%, or &lt;10% free FXI) at trough on Day 91 at different dose levels of MAA868</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of FXI at trough after first and second dose (Day 31 and Day 61) at different dose levels of MAA868</measure>
    <time_frame>Day 31 and Day 61</time_frame>
    <description>Occurrence of achieving ≥50%, ≥ 80%, and ≥90% inhibition of FXI (&lt;50%, &lt;20%, or &lt;10% free FXI) at trough on Day 31 and Day 61 at different dose levels of MAA868</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events following multiple subcutaneous administration of MAA868 compared to placebo in patients with atrial fibrillation</measure>
    <time_frame>Day 1 through end of study, up to 170 days</time_frame>
    <description>Occurrence of adverse events (AEs), including serious adverse events (SAEs) during the treatment period and through end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major bleeding events, clinically relevant non-major (CRNM) bleeding events and total bleeding with MAA868 relative to placebo</measure>
    <time_frame>Day 1 through end of study, up to 170 days</time_frame>
    <description>Occurrence of confirmed major bleeding events, clinically relevant non-major (CRNM) bleeding events and total bleeding events during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MAA868 compared to placebo</measure>
    <time_frame>Days 1, 31, 61, 71, 91, 121 and 170</time_frame>
    <description>Screening and confirmation for anti-drug (MAA868) antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>MAA868</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection on Day 1 with two subsequent monthly injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MAA868 Cohort 1</intervention_name>
    <description>Subcutaneous injection: low dose</description>
    <arm_group_label>MAA868</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MAA868 Cohort 2</intervention_name>
    <description>Subcutaneous injection: high dose</description>
    <arm_group_label>MAA868</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MAA868 Cohort 3</intervention_name>
    <description>Subcutaneous injection: Dose to be determined</description>
    <arm_group_label>MAA868</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection: Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients ≥ 18 and &lt; 85 years old with paroxysmal atrial fibrillation
             (PAF) or atrial flutter on 12 lead electrocardiography at Screening Or

          -  Patients with a history of PAF or atrial flutter, as documented by (telemetry, 12 lead
             electrocardiography or ambulatory [e.g. Holter] monitor) and not due to a reversible
             condition (e.g. alcohol binge drinking) can be entered even if they do not have PAF at
             Screening. There is not time-limit for this.

          -  Patients with a Congestive heart failure, Hypertension, Age ( &gt; 65 = 1 point, &gt; 75 = 2
             points), Diabetes, previous Stroke/transient ischemic attack (2 points) (CHA2DS2-VASc)
             risk score (tool as a predictor for estimating the risk of stroke in patients with
             atrial fibrillation (AF); Lip et al 2010) of 0-1 for men and 1-2 for women and in
             whom, in the investigator's judgment, the use of an anticoagulant for stroke
             prevention is not indicated

        Exclusion Criteria:

          -  History of stroke, transient ischemic attack or systemic embolism

          -  History of major bleeding during treatment with an anticoagulant or antiplatelet
             therapy. (Patients who have had major bleeding on anticoagulants or antiplatelet
             therapy more than a year ago can be enrolled only if the bleeding was due to a
             reversible cause, e.g. gastro-duodenal ulcer that was successfully treated.)

          -  History of traumatic or non-traumatic intracranial, intraspinal or intraocular
             bleeding

          -  Known bleeding diathesis or any known active bleeding site at screening or baseline

          -  Family history of bleeding disorder

          -  Known active GI lesions predisposing to bleeding events

          -  Myocardial infarction, unstable angina pectoris or coronary artery bypass graft (CABG)
             surgery within 12 months prior to the Screening period

          -  Known clinically significant valvular heart disease including moderate or severe
             mitral stenosis (valve area &lt;1.5 cm2)

          -  Patients with a prosthetic heart valve

        Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nancy Widener</last_name>
    <phone>239-284-3741</phone>
    <email>Nancy.w@anthostherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@anthostherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@anthostherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@anthostherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@anthostherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@anthostherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@anthostherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@anthostherapeutics.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>flutter</keyword>
  <keyword>paroxysmal atrial fibrillation</keyword>
  <keyword>stroke</keyword>
  <keyword>cardiac arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

